[开放获取]    老年银屑病诊疗与康复专家共识（2026版）

doi:10.35541/cjd.20250637

Abstract

Abstract: 【Abstract】 With the accelerating pace of population aging, the clinical management of psoriasis in the elderly is facing new challenges and opportunities. As an immune?mediated chronic inflammatory systemic disease, psoriasis in the elderly is characterized by a prolonged disease course, complex comorbidities, and increased treatment difficulty. To standardize the clinical diagnosis, treatment, and rehabilitation management of psoriasis in the elderly, the Chinese Association of Rehabilitation Dermatology and the Combination of Traditional and Western Medicine Dermatology convened experts in related fields to develop the “expert consensus on the diagnosis, treatment and rehabilitation of psoriasis in the elderly （2026 edition）”, drawing on the latest clinical research evidence and advances in evidence?based medicine. This consensus focuses on providing practical recommendations for key aspects of geriatric psoriasis management, including disease assessment, individualized treatment strategies, coordinated management of comorbidities, medication safety monitoring, and rehabilitation interventions. The aim is to enhance clinicians' capacity for comprehensive management of psoriasis in the elderly, improve clinical outcomes, and ultimately elevate patients' quality of life.

Key words: Psoriasis, Aged, Diagnosis, Therapy, Rehabilitation, Consensus

Chinese Association of Rehabilitation Dermatology, Combination of Traditional and Western Medicine Dermatology. Expert consensus on the diagnosis, treatment and rehabilitation of psoriasis in the elderly （2026 edition）[J]. Chinese Journal of Dermatology,2026,e20250637. doi:10.35541/cjd.20250637

References ［85］

［1］	Griffiths C, Armstrong AW, Gudjonsson JE, et al. Psoriasis［J］. Lancet, 2021,397（10281）:1301⁃1315. DOI: 10.1016/S0140⁃6736（20）32549⁃6.
［2］	Wang K, Zhao Y, Cao X. Global burden and future trends in psoriasis epidemiology: insights from the global burden of disease study 2019 and predictions to 2030［J］. Arch Dermatol Res, 2024,316（4）:114. DOI: 10.1007/s00403⁃024⁃02846⁃z.
［3］	Tang Z, Li X, Cai L, et al. Psoriasis burden trends and future projections in China: global burden of disease study 2021［J］. Arch Dermatol Res, 2025,317（1）:256. DOI: 10.1007/s00403⁃025⁃03810⁃1.
［4］	Burshtein J, Strunk A, Garg A. Incidence of psoriasis among adults in the United States: a sex⁃ and age⁃adjusted population analysis［J］. J Am Acad Dermatol, 2021,84（4）:1023⁃1029. DOI: 10.1016/j.jaad.2020.11.039.
［5］	Phan C, Sigal ML, Estève E, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis［J］. J Eur Acad Dermatol Venereol, 2016,30（1）:78⁃82. DOI: 10.1111/jdv.12850.
［6］	Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over the age of 60 years: is elderly⁃onset psoriasis a distinct subtype?［J］. Int J Dermatol, 2012,51（1）:53⁃58. DOI: 10.1111/j.1365⁃4632.2011.04979.x.
［7］	Grozdev IS, Van Voorhees AS, Gottlieb AB, et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation［J］. J Am Acad Dermatol, 2011,65（3）:537⁃545. DOI: 10.1016/j.jaad.2010.05.014.
［8］	Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital⁃based case⁃control study［J］. Br J Dermatol, 2007,157（1）:68⁃73. DOI: 10.1111/j.1365⁃2133.2007.07986.x.
［9］	Finstad A, Glockler⁃Lauf SD, Almuhanna N, et al. Investigating the risk of malignancy in elderly patients with psoriasis: a population⁃based retrospective matched cohort study［J］. J Am Acad Dermatol, 2023,88（5）:1129⁃1131. DOI: 10.1016/j.jaad. 2022.08.017.
［10］	Sampogna F, Chren MM, Melchi CF, et al. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis［J］. Br J Dermatol, 2006,154（2）:325⁃331. DOI: 10. 1111/j.1365⁃2133.2005.06909.x.
［11］	Çalışkan E, Edek YC, Keskin N, et al. Geriatric psoriasis: evaluation of clinical features, disease course, and treatment modalities of patients from a tertiary care hospital［J］. Dermatol Pract Concept, 2025,15（1）:4511. DOI: 10.5826/dpc.1501a4511.
［12］	Ricardo JW, Lipner SR. Nail psoriasis in older adults: epidemiology, diagnosis, and topical therapy［J］. Dermatol Clin, 2021,39（2）:183⁃193. DOI: 10.1016/j.det.2020.12.011.
［13］	Yamamoto T. Erythroderma in the elderly［J］. J Dermatol, 2025,52（2）:221⁃227. DOI: 10.1111/1346⁃8138.17538.
［14］	Caso F, Tasso M, Chimenti MS, et al. Late⁃onset and elderly psoriatic arthritis: clinical aspects and management［J］. Drugs Aging, 2019,36（10）:909⁃925. DOI: 10.1007/s40266⁃019⁃00688⁃3.
［15］	Li M, Wang J, Liu Q, et al. Beyond the dichotomy: understanding the overlap between atopic dermatitis and psoriasis［J］. Front Immunol, 2025,16:1541776. DOI: 10.3389/fimmu.2025.1541776.
［16］	Al⁃Janabi A, Foulkes AC, Mason K, et al. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review［J］. J Eur Acad Dermatol Venereol, 2020,34（7）:1440⁃1448. DOI: 10.1111/jdv.16246.
［17］	Murphy MJ, Cohen JM, Vesely MD, et al. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis［J］. J Am Acad Dermatol, 2022,86（5）:1080⁃1091. DOI: 10.1016/j.jaad.2020.12.010.
［18］	Cohen JN, Bowman S, Laszik ZG, et al. Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: a retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β⁃defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor⁃associated dermatitis［J］. J Am Acad Dermatol, 2020,82（2）:430⁃439. DOI: 10.1016/j.jaad.2019.08.023.
［19］	Khalil FK, Keehn CA, Saeed S, et al. Verrucous psoriasis: a distinctive clinicopathologic variant of psoriasis［J］. Am J Dermatopathol, 2005,27（3）:204⁃207. DOI: 10.1097/01.dad. 0000157450.39033.31.
［20］	Yosipovitch G, Tang MB. Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options［J］. Drugs Aging, 2002,19（11）:847⁃863. DOI: 10.2165/00002512⁃200219110⁃00003.
［21］	Balak DM, Hajdarbegovic E. Drug⁃induced psoriasis: clinical perspectives［J］. Psoriasis （Auckl）, 2017,7:87⁃94. DOI: 10. 2147/PTT.S126727.
［22］	Gui XY, Yu XL, Jin HZ, et al. Prevalence of metabolic syndrome in Chinese psoriasis patients: a hospital⁃based cross⁃sectional study［J］. J Diabetes Investig, 2018,9（1）:39⁃43. DOI: 10.1111/jdi.12663.
［23］	Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review［J］. JAMA, 2020,323（19）:1945⁃1960. DOI: 10.1001/jama.2020.4006.
［24］	Tseng IL, Yang CC, Lai EC, et al. Psoriasis in the geriatric population: a retrospective study in Asians［J］. J Dermatol, 2021,48（6）:818⁃824. DOI: 10.1111/1346⁃8138.15737.
［25］	van der Voort EA, Koehler EM, Dowlatshahi EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population⁃based study［J］. J Am Acad Dermatol, 2014,70（3）:517⁃524. DOI: 10.1016/j.jaad.2013.10.044.
［26］	Vaengebjerg S, Skov L, Egeberg A, et al. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2020,156（4）:421⁃429. DOI: 10.1001/jamadermatol. 2020.0024.
［27］	Saalbach A, Kunz M. Impact of chronic inflammation in psoriasis on bone metabolism［J］. Front Immunol, 2022,13:925503. DOI: 10.3389/fimmu.2022.925503.
［28］	Yiu Z, Sorbe C, Lunt M, et al. Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy［J］. Br J Dermatol, 2019,180（4）:894⁃901. DOI: 10.1111/bjd.17421.
［29］	Wen S, Elias PM, Wakefield JS, et al. The link between cutaneous inflammation and cognitive impairment［J］. J Eur Acad Dermatol Venereol, 2022,36（10）:1705⁃1712. DOI: 10. 1111/jdv.18360.
［30］	王宏伟, 王秀丽. 伍德灯皮肤科实用技术图解［M］. 上海: 上海科学技术出版社, 2014.
［31］	Wang ZY, Shen CB, Fei WM, et al. Accuracy of dermoscopic and reflectance confocal microscopic criteria for diagnosis of psoriasis［J］. Chin Med J （Engl）, 2020,133（24）:3010⁃3012. DOI: 10.1097/CM9.0000000000001198.
［32］	Wu Y, Sun L. Clinical value of dermoscopy in psoriasis［J］. J Cosmet Dermatol, 2024,23（2）:370⁃381. DOI: 10.1111/jocd. 15926.
［33］	Golińska J, Sar⁃Pomian M, Rudnicka L. Diagnostic accuracy of trichoscopy in inflammatory scalp diseases: a systematic review［J］. Dermatology, 2022,238（3）:412⁃421. DOI: 10.1159/00051 7516.
［34］	Hwang JK, Grover C, Iorizzo M, et al. Nail psoriasis and nail lichen planus: updates on diagnosis and management［J］. J Am Acad Dermatol, 2024,90（3）:585⁃596. DOI: 10.1016/j.jaad. 2023.11.024.
［35］	Hoogedoorn L, Wolberink EA, van de Kerkhof PC, et al. Noninvasive differentiation between stable and unstable chronic plaque psoriasis using in vivo reflectance confocal microscopy［J］. J Am Acad Dermatol, 2015,73（5）:870⁃872. DOI: 10.1016/j.jaad.2015.07.038.
［36］	Kim DH, Rockwood K. Frailty in older adults［J］. N Engl J Med, 2024,391（6）:538⁃548. DOI: 10.1056/NEJMra2301292.
［37］	Wang X, Weng W, Yan Z, et al. Association between the frailty index and psoriasis: a cross⁃sectional study of the U.S. NHANES 2003⁃2006［J］. J Frailty Aging, 2026,15（1）:100102. DOI: 10. 1016/j.tjfa.2025.100102.
［38］	Korman NJ. Management of psoriasis as a systemic disease: what is the evidence?［J］. Br J Dermatol, 2020,182（4）:840⁃848. DOI: 10.1111/bjd.18245.
［39］	Takeshita J, Wang S, Shin DB, et al. Effect of psoriasis severity on hypertension control: a population⁃based study in the United Kingdom［J］. JAMA Dermatol, 2015,151（2）:161⁃169. DOI: 10. 1001/jamadermatol.2014.2094.
［40］	Friis NU, Hoffmann N, Gyldenløve M, et al. Glucose metabolism in patients with psoriasis［J］. Br J Dermatol, 2019,180（2）:264⁃271. DOI: 10.1111/bjd.17349.
［41］	Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias［J］. Eur Heart J, 2025,46（42）:4359⁃4378. DOI: 10.1093/eurheartj/ehaf190.
［42］	Carrascosa JM, Vilarrasa E, Belinchón I, et al. Common approach to metabolic⁃associated fatty liver disease in patients with psoriasis: consensus⁃based recommendations from a multidisciplinary group of experts［J］. Actas Dermosifiliogr, 2023,114（5）:T392⁃T401. DOI: 10.1016/j.ad.2023.04.013.
［43］	中国医师协会骨科医师分会骨质疏松学组, 中华医学会骨科学分会青年骨质疏松学组, 中华预防医学会健康传播分会, 等. 中国人群骨质疏松症风险管理公众指南（2024）［J］. 中华骨质疏松和骨矿盐疾病杂志, 2024,17（6）:533⁃548. DOI: 10. 3760/cma.j.cn115530⁃20240630⁃00275.
［44］	Chandran V, Abji F, Perruccio AV, et al. Serum⁃based soluble markers differentiate psoriatic arthritis from osteoarthritis［J］. Ann Rheum Dis, 2019,78（6）:796⁃801. DOI: 10.1136/annrheumdis⁃ 2018⁃214737.
［45］	Kharouf F, Gladman DD. Advances in the management of psoriatic arthritis in adults［J］. BMJ, 2024,387:e081860. DOI: 10.1136/bmj⁃2024⁃081860.
［46］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂及小分子药物治疗指南（2024版）［J］. 中华皮肤科杂志, 2024,57（11）:976⁃997. DOI: 10.35541/cjd.20240294.
［47］	Mataix J, García L, Belinchón I, et al. Moderate to severe psoriasis in older adults: recommendations on management from the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology （AEDV）［J］. Actas Dermosifiliogr, 2023,114（9）:T802⁃T811. DOI: 10.1016/j.ad.2023.07.016.
［48］	Elmets CA, Korman NJ, Prater EF, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures［J］. J Am Acad Dermatol, 2021,84（2）:432⁃470. DOI: 10.1016/j.jaad.2020.07.087.
［49］	Shen J, Zhou W, Zhang H, et al. The impact of a skin management model based on a precision quantitative ointment dispenser on skin symptoms and quality of life in elderly psoriasis patients［J］. J Dermatolog Treat, 2025,36（1）:2474505. DOI: 10.1080/09546634.2025.2474505.
［50］	Kulawik⁃Pióro A, Miastkowska M. Polymeric gels and their application in the treatment of psoriasis vulgaris: a review［J］. Int J Mol Sci, 2021,22（10）:5124. DOI: 10.3390/ijms22105124.
［51］	Alabas OA, Mason KJ, Yiu Z, et al. The association of age at psoriasis onset and HLA⁃C*06:02 with biologic survival in patients with moderate⁃to⁃severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register （BADBIR）［J］. Br J Dermatol, 2024,190（5）:689⁃700. DOI: 10.1093/bjd/ljad481.
［52］	Armstrong AW, Blauvelt A, Lebwohl M, et al. Efficacy and safety of tildrakizumab in patients with early⁃ vs. late⁃onset psoriasis［J］. Br J Dermatol, 2025,193（3）:442⁃450. DOI: 10. 1093/bjd/ljaf171.
［53］	Ruggiero A, Fabbrocini G, Cinelli E, et al. Anti⁃interleukin⁃23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real⁃world practice［J］. Clin Exp Dermatol, 2022,47（3）:561⁃567. DOI: 10.1111/ced.14979.
［54］	Al⁃Janabi A, Alabas OA, Yiu Z, et al. Risk of paradoxical eczema in patients receiving biologics for psoriasis［J］. JAMA Dermatol, 2024,160（1）:71⁃79. DOI: 10.1001/jamadermatol.2023. 4846.
［55］	Talamonti M, Russo F, Malara G, et al. Efficacy and safety of secukinumab in elderly patients with moderate to severe plaque⁃type psoriasis: post⁃hoc analysis of the SUPREME study［J］. Clin Cosmet Investig Dermatol, 2023,16:847⁃852. DOI: 10.2147/CCID.S400520.
［56］	Minami Y, Hiruma J, Harada K, et al. Risk of fungal infection in patients with psoriasis receiving biologics: a retrospective single⁃center cohort study［J］. J Am Acad Dermatol, 2025,92（1）:108⁃115. DOI: 10.1016/j.jaad.2024.09.037.
［57］	Menter A, Gordon KB, Leonardi CL, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis［J］. J Am Acad Dermatol, 2010,63（3）:448⁃456. DOI: 10.1016/j.jaad.2009.09.040.
［58］	van Onna M, Boonen A. Challenges in the management of older patients with inflammatory rheumatic diseases［J］. Nat Rev Rheumatol, 2022,18（6）:326⁃334. DOI: 10.1038/s41584⁃022⁃00768⁃6.
［59］	Cho SK, Sung YK, Kim D, et al. Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis［J］. BMC Musculoskelet Disord, 2016,17:333. DOI: 10.1186/s12891⁃016⁃1185⁃6.
［60］	Hsieh DM, Shang P, Gao Y, et al. Successful treatment with spesolimab for generalized pustular psoriasis in an elderly patient with TRPM4 mutation［J］. J Dermatol, 2025,52（2）:e151⁃e152. DOI: 10.1111/1346-8138.17431.
［61］	Sharma A, Pandoh N, Dayal K, et al. PDE4 inhibitors in psoriasis therapy: current insights and future directions［J］. Inflammopharmacology, 2025,33（6）:2885⁃2906. DOI: 10.1007/s10787⁃025⁃01778⁃y.
［62］	Cheng W, Pan C, Xu Q, et al. Spongiotic psoriasiform dermatitis with dual features of eczema and psoriasis: Janus kinase inhibition as a potential therapeutic option［J］. Clin Exp Dermatol, 2025,50（12）:2431⁃2438. DOI: 10.1093/ced/llaf336.
［63］	Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52⁃week, randomized, double⁃blinded, placebo⁃controlled phase 3 POETYK PSO⁃1 trial［J］. J Am Acad Dermatol, 2023,88（1）:29⁃39. DOI: 10.1016/j.jaad.2022.07.002.
［64］	Traves PG, Murray B, Campigotto F, et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib［J］. Ann Rheum Dis, 2021,80（7）:865⁃875. DOI: 10.1136/annrheumdis⁃2020⁃219012.
［65］	Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly［J］. Expert Opin Biol Ther, 2018,18（8）:897⁃903. DOI: 10.1080/14712598. 2018.1504016.
［66］	Sarkar R, Chugh S, Garg VK. Acitretin in dermatology［J］. Indian J Dermatol Venereol Leprol, 2013,79（6）:759⁃771. DOI: 10.4103/0378⁃6323.120721.
［67］	Warren RB, Weatherhead SC, Smith CH, et al. British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016［J］. Br J Dermatol, 2016,175（1）:23⁃44. DOI: 10.1111/bjd.14816.
［68］	Ichinose K. The interplay between rheumatoid arthritis and chronic kidney disease: from mechanisms to treatment［J］. J Clin Med, 2025,15（1）:108. DOI: 10.3390/jcm15010108.
［69］	Mehta D, Lim HW. Ultraviolet B phototherapy for psoriasis: review of practical guidelines［J］. Am J Clin Dermatol, 2016,17（2）:125⁃133. DOI: 10.1007/s40257⁃016⁃0176⁃6.
［70］	Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology⁃National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy［J］. J Am Acad Dermatol, 2019,81（3）:775⁃804. DOI: 10.1016/j.jaad.2019.04.042.
［71］	Otto M, Dorn B, Grasmik T, et al. Apremilast effectively inhibits TNFα⁃induced vascular inflammation in human endothelial cells［J］. J Eur Acad Dermatol Venereol, 2022,36（2）:237⁃246. DOI: 10.1111/jdv.17769.
［72］	Choi H, Uceda DE, Dey AK, et al. Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid⁃rich necrotic core: results from a prospective, observational study［J］. Circ Cardiovasc Imaging, 2020,13（9）:e011199. DOI: 10.1161/CIRCIMAGING.120.011199.
［73］	Paschou IA, Sali E, Paschou SA, et al. The effects of GLP⁃1RA on inflammatory skin diseases: a comprehensive review［J］. J Eur Acad Dermatol Venereol, 2025,39（12）:2047⁃2055. DOI: 10.1111/jdv.20694.
［74］	Veronesi G, Guglielmo A, Gardini A, et al. Biological therapy in patients with psoriasis: what we know about the effects on renal function［J］. Dermatol Ther, 2022,35（1）:e15202. DOI: 10.1111/dth.15202.
［75］	Kottner J, Lichterfeld A, Blume⁃Peytavi U. Maintaining skin integrity in the aged: a systematic review［J］. Br J Dermatol, 2013,169（3）:528⁃542. DOI: 10.1111/bjd.12469.
［76］	Wang Q, Wang J, Sun X, et al. Evidence⁃based dietary recommendations for patients with psoriasis: a systematic review［J］. Clin Nutr, 2025,47:68⁃82. DOI: 10.1016/j.clnu.2025.02.005.
［77］	Barrea L, Savanelli MC, Di Somma C, et al. Vitamin D and its role in psoriasis: an overview of the dermatologist and nutritionist［J］. Rev Endocr Metab Disord, 2017,18（2）:195⁃205. DOI: 10.1007/s11154⁃017⁃9411⁃6.
［78］	Villareal DT, Aguirre L, Gurney AB, et al. Aerobic or resistance exercise, or both, in dieting obese older adults［J］. N Engl J Med, 2017,376（20）:1943⁃1955. DOI: 10.1056/NEJMoa1616338.
［79］	Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis［J］. Arthritis Rheumatol, 2019,71（1）:5⁃32. DOI: 10.1002/art.40726.
［80］	Mitchell AJ, Bird V, Rizzo M, et al. Diagnostic validity and added value of the Geriatric Depression Scale for depression in primary care: a meta⁃analysis of GDS30 and GDS15［J］. J Affect Disord, 2010,125（1⁃3）:10⁃17. DOI: 10.1016/j.jad.2009.08.019.
［81］	Lavda AC, Webb TL, Thompson AR. A meta⁃analysis of the effectiveness of psychological interventions for adults with skin conditions［J］. Br J Dermatol, 2012,167（5）:970⁃979. DOI: 10. 1111/j.1365⁃2133.2012.11183.x.
［82］	Endo JO, Wong JW, Norman RA, et al. Geriatric dermatology: partⅠ. Geriatric pharmacology for the dermatologist［J］. J Am Acad Dermatol, 2013,68（4）:521.e1⁃521.e10. DOI: 10.1016/j.jaad.2012.10.063.
［83］	Chat VS, Ellebrecht CT, Kingston P, et al. Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation［J］. J Am Acad Dermatol, 2024,90（6）:1170⁃1181. DOI: 10.1016/j.jaad.2023.12.070.
［84］	Park JK, Lee YJ, Shin K, et al. A multicenter, prospective, randomized, parallel⁃group trial on the effects of temporary methotrexate discontinuation for one week versus two weeks on seasonal influenza vaccination in patients with rheumatoid arthritis［J］. Arthritis Rheumatol, 2023,75（2）:171⁃177. DOI: 10.1002/art.42318.
［85］	James WA, Rosenberg AL, Wu JJ, et al. Full guidelines⁃from the Medical Board of the National Psoriasis Foundation: perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis［J］. J Am Acad Dermatol, 2024,91（2）:251.e1⁃251.e11. DOI: 10.1016/j.jaad.2024.03.008.

[1]	Liu Jia, Gu Yinghua, He Xiaoning, . Treatment and disease burden of hereditary angioedema [J]. Chinese Journal of Dermatology, 2026, 59(3): 282-286.
[2]	Liu Lihao, Hu Yu, Chen Kun. Clinical application and development of photobiomodulation in dermatology [J]. Chinese Journal of Dermatology, 2026, 59(3): 278-282.
[3]	Yang Wanqing, Chen Nuoran, Meng Xiaoqi, Liu Tingwei, Xu Yang. Application of focused ultrasound in dermatology beyond the anti?aging aspects [J]. Chinese Journal of Dermatology, 2026, 0(3): 20240433-e20240433.
[4]	Zeng Wanxin, Wen Xiang. Photoelectric therapy for hypertrophic scars [J]. Chinese Journal of Dermatology, 2026, 59(3): 269-273.
[5]	Xia Zhikuan, Ge Ge. Laser therapy for vitiligo: clinical applications and prospects [J]. Chinese Journal of Dermatology, 2026, 59(3): 213-217.
[6]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on management of psoriasis with comorbidities （2026） [J]. Chinese Journal of Dermatology, 2026, 59(3): 193-207.
[7]	Expert Group on the Interpretation of the "Chinese expert consensus on the clinical application of photobiomodulation therapy in dermatology （）", Laser Medicine Group, Chinese Society of Dermatology. Interpretation of the Chinese expert consensus on the clinical application of photobiomodulation therapy in dermatology （2025） [J]. Chinese Journal of Dermatology, 2026, 59(3): 208-212.
[8]	Wang Juncheng, Liu Jie. Artificial intelligence in psoriasis: diagnosis, treatment and patient management [J]. Chinese Journal of Dermatology, 2026, 0(3): 20240061-e20240061.
[9]	Xu Zhuohong, Zhou Huan, Hu Yu, Gu Heng. Balneotherapy in skin diseases [J]. Chinese Journal of Dermatology, 2026, 0(3): 20250531-e20250531.
[10]	Guo Lan, Jin Hongzhong. Tryptophan and arginine metabolism in immune regulation and their role in the pathogenesis of psoriasis [J]. Chinese Journal of Dermatology, 2026, 0(3): 20240377-e20240377.
[11]	Wang Li, Wang Qianqiu, Zhang Ruili. Research progress in latent syphilis [J]. Chinese Journal of Dermatology, 2026, 59(3): 286-289.
[12]	Chinese Society of Dermatology, China Dermatologist Association. Guidelines on the diagnosis and treatment of dermatitis and eczematous diseases in China （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(2): 97-106.
[13]	Environmental and Occupational Skin Disease Research Group, Chinese Dermatovenerology Society of Integrative Medicine, Committee on Dermatology, Chinese Association of Geriatric Research, Committee on Drugs for Dermatology, China Association of Traditional Chinese Medicine, Dermatology Branch of China Association for Promotion of Health Science and Technology. Expert consensus on rational application of moisturizers for atopic dermatitis （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(2): 107-112.
[14]	Chen Hao. Clinical histological characteristics of several novel cutaneous soft tissue neoplasms and their subtypes [J]. Chinese Journal of Dermatology, 2026, 59(2): 120-126.
[15]	Chinese Society of Dermatology, China Dermatologist Association, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, Rare Skin Diseases Committee, China Alliance for Rare Diseases. Expert consensus on spesolimab in the treatment of inflammatory skin diseases （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(2): 113-119.

Expert consensus on the diagnosis, treatment and rehabilitation of psoriasis in the elderly （2026 edition）

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［85］

Related Articles 15

Metrics

Comments

Recommended 0